Multiple Myeloma: Optimizing Outcomes for Patients on Monoclonal Antibody Therapy

Program Description
Monoclonal antibodies are approved for use in treating both newly diagnosed and relapsed/refractory multiple myeloma, with numerous combinations of therapy recommended in national guidelines. Therapy selection includes past treatments, candidacy for stem cell transplant, and other patient-specific factors. This activity will review the clinical data for incorporating monoclonal antibodies into the treatment paradigm of multiple myeloma. Additionally, the economic impact of monoclonal antibody therapy will be discussed, with an emphasis on strategies managed care pharmacists can implement to assist with formulary development.

Target Audience: Managed care pharmacists

Type of Activity: Application

Release date: November 1, 2021

Expiration date: November 1, 2022

Time to complete activity: 1.5 hours

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine recent FDA approvals and clinical trials incorporating monoclonal antibodies for multiple myeloma.
• Analyze clinical guidelines for monoclonal antibody use in newly diagnosed and relapsed/refractory multiple myeloma.
• Integrate multiple myeloma treatment outcomes with economic considerations to develop formulary management strategies.

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-377-H01-P. The activity is available for CE credit through November 1, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Melissa Pozotrigo, PharmD, BCOP

Kathryn Maples, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: GlaxoSmithKline, Sanofi

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Croom Taylor, PharmD; Liz Rauh; Susan Pordon; Brianna Winters; and Chloe Taccetta

Pharmacy Times^® Editorial Staff—Davy James

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms